Introduction
============

Endometriosis is an estrogen-dependent chronic benign disease that demonstrates characteristics of ovarian malignancy such as invasive growth, hormone dependency, and recurrence \[[@B1]\]. Although endometriosis remains largely benign, the malignant potential of endometriosis has been suggested with epidemiological, histopathological, and molecular data \[[@B2][@B3]\]. Previous studies reported an increased risk of ovarian cancer in women with endometriosis, predominantly for clear cell and endometrioid type histology \[[@B2][@B4][@B5]\]. In Korean women, age-standardized incidence rates for clear cell carcinoma (CCC) in all ages and endometrioid carcinoma (EC) in young age have increased according to recent data \[[@B6]\]. Increase in the CCC and EC type in Korean women might be explained with increase of endometriosis by westernization of diet and life styles leading to earlier menarche, increased obesity, and decreased childbearing in Korean women \[[@B7]\].

The pathologic findings of malignancy with endometriosis have been demonstrated in the literature since Sampson \[[@B8]\] first described them in 1925. In 1953, Scott \[[@B9]\] added criteria for the morphology of benign and malignant epithelia within endometriosis. Controversy remains regarding the possibility that endometriosis-associated cancers represent a distinct category from the typical histologic type. A number of studies have presented the tendency of patients with endometriosis to be diagnosed at a younger age, with earlier stage and lower grade lesions, and to have better survival outcomes \[[@B10][@B11][@B12][@B13]\]. However, other studies fail to demonstrate survival differences between groups with and without endometriosis \[[@B14][@B15]\] or the significance of association with endometriosis as an independent prognostic factor \[[@B16][@B17][@B18]\].

The present study evaluated the incidence of cancer arising from endometriosis in cases with clear cell and endometrioid type epithelial ovarian cancer (EOC) treated at single institution. We also investigated clinicopathological characteristics and survival outcomes in terms of progression-free survival (PFS) and overall survival (OS) compared to patients with cancer not arising from endometriosis.

MATERIALS and Methods
=====================

1. Patients and treatment {#sec1}
-------------------------

With Institutional Review Board approval (No. 2017-03-082), all patients with primary EOC who were treated at Samsung Medical Center from 2002 to 2015 were reviewed. Data from electronic medical records was retrospectively reviewed. Flowchart of included patients is shown in [Fig. 1](#F1){ref-type="fig"}. In this study, we included primary EOC patients with clear cell and endometrioid type histology among patients who had undergone primary treatment including primary debulking surgery (PDS) and adjuvant chemotherapy (AC). Patients who had concurrent cancer other than EOC were excluded from the study at the beginning of the process. A total of 224 patients were selected for this study. Among these, 41 patients (18.3%) were categorized in the group with cancer arising from endometriosis.

![Flowchart of included patients.\
AC, adjuvant chemotherapy; CCC, clear cell carcinoma; EC, endometrioid carcinoma; EOC, epithelial ovarian cancer; IDS, interval debulking surgery; NAC, neo-adjuvant chemotherapy; PDS, primary debulking surgery.](jgo-29-e18-g001){#F1}

Bilateral salpingo-oophorectomy, hysterectomy, peritoneal washing, retroperitoneal lymphadenectomy, omentectomy, and tumorectomy of any metastatic lesions were routinely performed for primary surgical treatment. If any abnormalities were suspected, peritoneal biopsies were performed for pathologic confirmation. To define residual disease status after PDS, the largest diameter of residual disease was measured and categorized as follows: no residual disease, 0.1--1 cm residual disease, and \>1 cm residual disease. For AC, first cycle combination chemotherapy consisting of taxane/platinum was routinely initiated within 2 weeks of surgery. Chemotherapy was continued every 3 weeks for 6 cycles, but there may have been variations in the number of cycles depending on the patient\'s situation. OS was defined as the time between diagnosis and either patient death or loss to follow-up. PFS was described as time between diagnosis and patient recurrence/progression or loss to follow-up.

Routinely, tumor tissue specimens were obtained during surgery, and resected tumor sections were fixed in 10% buffered formalin and embedded in paraffin. In all cases, at least one section was obtained for every 1 cm of maximal tumor diameter and processed after formalin fixation. Then the tumor tissue sections were cut into 3- to 4-μm slices and stained with hematoxylin and eosin. Gynecologic pathologists reviewed all surgical pathology slides with confirming that all samples contained more than 80% of the total tumor area with less than 20% of necrosis.

Patients were divided into 2 groups according to detection of cancer arising from ovarian endometriosis or not based on the Sampson and Scott criteria \[[@B8][@B9]\]: 1) The presence of both benign and neoplastic endometrial tissues in the tumor, 2) histological findings compatible with endometrial origin, 3) the discovery of no other primary tumor sites, and 4) morphologic demonstration of a continuum between benign and malignant epithelium.

2. Statistical analysis {#sec2}
-----------------------

Summary statistics were used to describe the data. Medians (range) or means (standard deviation) were used for continuous variables. After the Shapiro-Wilks test confirmed normal distributions, Mann-Whitney U test was used to compare median values and Student\'s t-test was used to compare mean values. Categorical variables were presented as frequencies (percentages). Fisher\'s exact test or χ^2^ test were used to analyze the distribution of characteristics according to association with endometriosis. Survival curve analyses were performed by the Kaplan-Meier method, and comparison was performed using the log-rank test. Cox proportional hazards model was used to perform univariate and multivariate analyses for evaluation of the prognostic significance of association with endometriosis and other clinicopathological features. Multivariate p-values were used to present the significance of each feature. To quantify the correlation between survival time and each independent feature, a 95% confidence interval (CI) was used. All p-values were 2-sided, and p-values less than 0.05 were considered statistically significant. Statistical analyses were performed using R 3.0.3 (R Foundation, Vienna, Austria; <http://www.R-project.org>).

After the total cohort analyses, propensity score matching was performed to further elucidate patient characteristics. Cases associated with endometriosis were 1:1 matched according to age, International Federation of Gynecology and Obstetrics (FIGO) stage, initial cancer antigen (CA)-125 level, American Society of Anesthesiologist (ASA) performance status, and residual disease status after cytoreductive surgery with the closest propensity patients without endometriosis. Propensity scores were calculated using a multivariable logistic regression model based on factors that demonstrated significant differences between the 2 groups in the total cohort.

Results
=======

1. Patient characteristics and associations with endometriosis {#sec1___1}
--------------------------------------------------------------

Among EOC patients treated in Samsung Medical Center between 2002 and 2015, 224 patients who were diagnosed with clear cell and endometrioid type histology were investigated. Of 224 patients, 41 patients had cancer arising from endometriosis and 183 patients did not have associated endometriosis based on the Sampson and Scott criteria.

At the time of this analysis, of 224 patients, 80 patients (35.7%) experienced relapse and 58 (25.9%) died after a median observation period of 55 months (range, 3--161 months). The clinical characteristics of patients are listed in [Table 1](#T1){ref-type="table"}; patients with cancer arising from endometriosis had a lower average age (45.1±7.3 vs. 49.2±10.3 years; p=0.003) and lower initial CA-125 level (307.1±588.4 vs. 556.7±1,056.6 U/mL; p=0.041) than those without endometriosis. Regarding CA-125 level, surgical procedures prior to primary cytoreduction were investigated, and there were no significant differences between 2 groups. Also, no significant differences were found regarding type of cytoreductive surgery, number of AC cycle, and platinum sensitivity. There were significant differences between patients with and without endometriosis for FIGO stage, grade, residual disease status, lymph node metastasis (LNM), and ASA physical status. Patients with cancer arising from endometriosis presented with a higher percentage of early-stage (stages I--II, 92.7% vs. 62.3%; p=0.002), lower grade (grades 1--2, 53.7% vs. 38.8%; p=0.033), no residual disease after PDS (87.8% vs. 56.8%; p=0.001), and negative LNM (82.9% vs. 59.0%; p=0.008) compared to those without endometriosis.

###### Characteristics of study cohorts

![](jgo-29-e18-i001)

  Characteristics                                    All patients (n=224)            Without endometriosis (n=183)   Arising from endometriosis (n=41)   p-value
  -------------------------------------------------- ------------------------------- ------------------------------- ----------------------------------- -----------
  Age (yr)                                           48.4±9.9                        49.2±10.3                       45.1±7.0                            0.003
  Histology                                                                                                                                              0.752
                                                     Clear cell                      107 (47.8)                      86 (47.0)                           21 (51.2)
                                                     Endometrioid                    117 (52.2)                      97 (53.0)                           20 (48.8)
  FIGO stage                                                                                                                                             0.002
                                                     I                               122 (54.5)                      91 (49.7)                           31 (75.6)
                                                     II                              30 (13.4)                       23 (12.6)                           7 (17.1)
                                                     III                             64 (28.6)                       62 (33.9)                           2 (4.9)
                                                     IV                              8 (3.6)                         7 (3.8)                             1 (2.4)
  Grade                                                                                                                                                  0.033
                                                     1                               39 (17.4)                       26 (14.2)                           13 (31.7)
                                                     2                               54 (24.1)                       45 (24.6)                           9 (22.0)
                                                     3                               131 (58.5)                      107 (61.2)                          19 (46.3)
  Initial CA-125 (U/mL)                              510.9±991.3                     556.7±1,056.6                   307.1±588.4                         0.041
  Residual disease status after PDS                                                                                                                      0.001
                                                     No residual disease             140 (62.5)                      104 (56.8)                          36 (87.8)
                                                     0.1--1 cm residual disease      60 (26.8)                       56 (30.6)                           4 (9.8)
                                                     \>1 cm residual disease         24 (10.7)                       23 (12.6)                           1 (2.4)
  LNM                                                                                                                                                    0.008
                                                     Negative                        142 (63.4)                      108 (59.0)                          34 (82.9)
                                                     Positive                        21 (9.4)                        21 (11.5)                           0
                                                     Not done                        61 (27.2)                       54 (29.5)                           7 (17.1)
  ASA physical status                                                                                                                                    0.001
                                                     I                               114 (50.9)                      94 (51.4)                           20 (48.8)
                                                     II                              61 (27.2)                       56 (30.6)                           5 (12.2)
                                                     III                             6 (2.7)                         6 (3.3)                             0
                                                     Unknown                         43 (19.2)                       27 (14.8)                           16 (39.0)
  Type of cytoreductive surgery                                                                                                                          0.641
                                                     Complete staging                216 (96.4)                      177 (96.7)                          39 (95.1)
                                                     Fertility saving surgery        8 (3.6)                         6 (3.3)                             2 (4.9)
  Surgical procedures before cytoreductive surgery                                                                                                       0.938
                                                     None                            196 (87.5)                      160 (87.4)                          36 (87.8)
                                                     Unilateral oophorectomy         20 (8.9)                        16 (8.7)                            4 (9.8)
                                                     Bilateral oophorectomy          2 (0.9)                         2 (1.1)                             0
                                                     Unilateral ovarian cystectomy   6 (2.7)                         5 (2.7)                             1 (2.4)
  No. of AC cycle                                                                                                                                        0.376
                                                     4--6                            172 (76.8)                      143 (78.1)                          29 (70.7)
                                                     1--3                            22 (9.8)                        18 (9.8)                            4 (9.8)
                                                     None                            30 (13.4)                       22 (12.0)                           8 (19.5)
  Platinum sensitivity                                                                                                                                   0.545
                                                     Resistant                       13 (5.8)                        12 (6.6)                            1 (2.4)
                                                     Sensitive                       176 (78.6)                      144 (78.7)                          32 (78.0)
                                                     Unknown                         35 (15.6)                       27 (14.8)                           8 (19.5)

Data are shown as mean±standard deviation or number (%).

AC, adjuvant chemotherapy; ASA, American Society of Anesthesiologist; CA, cancer antigen; FIGO, International Federation of Gynecology and Obstetrics; LNM, lymph node metastasis; PDS, primary debulking surgery.

2. Survival comparison according to association with endometriosis and multivariate analysis for PFS and OS {#sec2___1}
-----------------------------------------------------------------------------------------------------------

Survival analysis of 224 patients with EC and CCC revealed significant differences in PFS and OS between patients with and without associated endometriosis ([Fig. 2](#F2){ref-type="fig"}). The Kaplan-Meier curve for PFS showed a survival advantage for patients with cancer arising from endometriosis (median, 57.3 vs. 35.0 months; p=0.014; [Fig. 2A](#F2){ref-type="fig"}). Results for OS indicated that patients with cancer arising from endometriosis had better survival outcomes compared to patients without associated endometriosis (median, 57.3 vs. 54.9 months; p=0.010; [Fig. 2B](#F2){ref-type="fig"}).

![Kaplan-Meier curve for (A) PFS and (B) OS in all patients.\
PFS, progression-free survival; OS, overall survival.](jgo-29-e18-g002){#F2}

In multivariate analysis of clinicopathologic variables in the entire cohort, cancer arising from endometriosis was not a significant prognostic factor for PFS (p=0.347) and OS (p=0.247) ([Table 2](#T2){ref-type="table"}). Previously known prognostic factors in EOC, such as FIGO stage and residual disease after PDS, remained significant prognostic factors for PFS and OS in this study cohort. Additionally, initial CA-125 level was significant in multivariate analysis for OS.

###### Multivariate Cox proportional hazards analysis for PFS and OS used to adjust risk associated prognostic clinical features

![](jgo-29-e18-i002)

  All patients (n=224)                PFS                          OS                                                                   
  ----------------------------------- ---------------------------- ---------------------- ---------------------- ---------------------- ---------
  Age (continuous)                    0.985 (0.962--1.009)         0.212                  0.977 (0.951--1.004)   0.100                  
  Initial CA-125 level (U/mL)                                                                                                           
                                      \<35                         1.000                  \-                     1.000                  \-
                                      ≥35                          1.920 (0.983--3.752)   0.056                  2.834 (1.055--7.611)   0.039
  FIGO stage                                                                                                                            
                                      I/II                         1.000                  \-                     1.000                  \-
                                      III/IV                       2.857 (1.634--4.995)   \<0.001                4.033 (2.007--8.107)   \<0.001
  Grade                                                                                                                                 
                                      1                            1.000                  \-                     1.000                  \-
                                      2                            1.923 (0.758--4.878)   0.168                  1.938 (0.545--6.893)   0.307
                                      3                            2.233 (0.923--5.405)   0.075                  2.530 (0.751--8.526)   0.134
  Residual disease status after PDS                                                                                                     
                                      No residual disease          1.000                  \-                     1.000                  \-
                                      0.1--1 cm residual disease   1.996 (1.161--3.432)   0.012                  2.743 (1.361--5.527)   0.005
                                      \>1 cm residual disease      2.806 (1.422--5.534)   0.003                  3.869 (1.731--8.651)   0.001
  Arising from endometriosis                                                                                                            
                                      No                           1.000                  \-                     1.000                  \-
                                      Yes                          0.675 (0.297--1.532)   0.347                  0.483 (0.145--1.613)   0.237

CA, cancer antigen; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; OS, overall survival; PDS, primary debulking surgery; PFS, progression-free survival.

3. Comparison after propensity score matching {#sec3}
---------------------------------------------

To reduce selection bias when comparing 2 groups of patients, propensity score matching was performed with R using the MatchIt package with nearest-neighbor 1-to-1 matching according to age, FIGO stage, CA-125 level, ASA performance status, and residual disease status after PDS. Matching was successful without significant differences between the 2 groups in all matched variables ([Table 3](#T3){ref-type="table"}). After propensity score matching, there were 82 patients; 41 had cancer arising from endometriosis and 41 had cancer without associated endometriosis. No significant differences were observed between the 2 groups in age, stage, grade, initial serum CA-125 level, residual disease status, LNM, and ASA physical status. Propensity score distribution and histograms of propensity scores before and after matching are shown in Supplementary Figs. 1 and 2.

###### Patient characteristics after propensity score matching

![](jgo-29-e18-i003)

  Characteristics                                    Without endometriosis (n=41)    Arising from endometriosis (n=41)   p-value
  -------------------------------------------------- ------------------------------- ----------------------------------- -----------
  Age (yr)                                           46.7±10.3                       45.1±7.0                            0.403
  Histology                                                                                                              0.752
                                                     Clear cell                      20 (48.8)                           21 (51.2)
                                                     Endometrioid                    21 (51.2)                           20 (48.8)
  FIGO stage                                                                                                             0.896
                                                     I                               29 (70.7)                           31 (75.6)
                                                     II                              7 (17.1)                            7 (17.1)
                                                     III                             3 (7.3)                             2 (4.9)
                                                     IV                              2 (4.9)                             1 (2.4)
  Grade                                                                                                                  0.272
                                                     1                               7 (17.1)                            13 (31.7)
                                                     2                               7 (17.1)                            9 (22.0)
                                                     3                               27 (65.8)                           19 (46.3)
  Initial CA-125 (U/mL)                              367.7±745.9                     307.1±588.4                         0.684
  Residual disease status after PDS                                                                                      0.222
                                                     No residual disease             40 (97.6)                           36 (87.8)
                                                     0.1--1 cm residual disease      1 (2.4)                             4 (9.8)
                                                     \>1 cm residual disease         0                                   1 (2.4)
  LNM                                                                                                                    \>0.999
                                                     Negative                        33 (80.5)                           34 (82.9)
                                                     Positive                        0                                   0
                                                     Not done                        8 (19.5)                            7 (17.1)
  ASA physical status                                                                                                    0.179
                                                     I                               15 (36.6)                           20 (48.8)
                                                     II                              12 (29.3)                           5 (12.2)
                                                     III                             1 (2.4)                             0
                                                     unknown                         13 (31.7)                           16 (39.0)
  Type of cytoreductive surgery                                                                                          \>0.999
                                                     Complete staging                40 (97.6)                           39 (95.1)
                                                     Fertility saving surgery        1 (2.4)                             2 (4.9)
  Surgical procedures before cytoreductive surgery                                                                       \>0.999
                                                     None                            35 (85.4)                           36 (87.8)
                                                     Unilateral oophorectomy         5 (12.2)                            4 (9.8)
                                                     Unilateral ovarian cystectomy   1 (2.4)                             1 (2.4)
  No. of AC cycle                                                                                                        \>0.999
                                                     4--6                            30 (73.2)                           29 (70.7)
                                                     1--3                            4 (9.8)                             4 (9.8)
                                                     None                            7 (17.1)                            8 (19.5)
  Platinum sensitivity                                                                                                   \>0.999
                                                     Resistant                       2 (4.9)                             1 (2.4)
                                                     Sensitive                       31 (75.6)                           32 (78.0)
                                                     Unknown                         8 (19.5)                            8 (19.5)

Data are shown as mean±standard deviation or number (%).

AC, adjuvant chemotherapy; ASA, American Society of Anesthesiologist; CA, cancer antigen; FIGO, International Federation of Gynecology and Obstetrics; LNM, lymph node metastasis; PDS, primary debulking surgery.

After propensity score matching, survival differences between the 2 groups were not significant. Kaplan-Meier curves for PFS and OS are shown in [Fig. 3](#F3){ref-type="fig"}, and p-values were 0.593 and 0.690, respectively.

![Kaplan-Meier curve for (A) PFS and (B) OS in patients after propensity score matching.\
PFS, progression-free survival; OS, overall survival.](jgo-29-e18-g003){#F3}

Discussion
==========

This study investigated patients with CCC and EC of the ovary and cancer arising from endometriosis. Patients with cancer arising from endometriosis presented with a lower average age, higher percentage of early-stage, lower grade, and no residual disease after PDS compared to those without endometriosis. PFS and OS indicated better survival outcomes for cancer arising from endometriosis. However, in multivariate analysis for PFS and OS, cancer arising from endometriosis was not statistically significant as an independent prognostic factor, and the results of propensity score matching showed that survival differences between the 2 groups were not significant, suggesting endometriosis as a possible precursor of EOC but not a factor that exacerbates cancer after its onset.

In previous studies, endometriosis-associated EOC cases were typically associated with early-stage, low-grade disease that may be related to better survival results \[[@B2][@B10][@B11][@B12][@B13]\]. However, the association with endometriosis remains controversial as an independent prognostic factor after calibrating related clinical situations. In a study by Bounous et al. \[[@B17]\], endometriosis-associated cancer presented with early-stage, and OS was significantly longer in EOC patients associated with endometriosis. After stratification by stage, the survival advantages of endometriosis-associated cancer patients disappeared. Conversely, a recent study showed cancer arising from endometriosis as an independent prognostic factor for PFS and OS. Furthermore, prognostic nomograms with endometriosis as a significant factor were provided \[[@B13]\]. In the current study, patients with cancer arising from endometriosis showed longer PFS and OS than another patient group. After propensity score matching, differences in survival outcomes between the 2 groups were not significant, and cancer arising from endometriosis was not an independent significant factor in multivariate analysis. This study is a continuation of these previous studies and was intended to provide additional information about cancer arising from endometriosis in EOC patients.

In this study, patients with cancer arising from endometriosis were diagnosed at an early-stage, which were consistent result with previous literatures \[[@B2][@B18][@B19][@B20]\]. The reason for diagnosis of early-stage could be due to the signs and symptoms related endometriosis (such as pelvic pain and adnexal mass) or concurrent presences of endometrial lesions (polyps, hyperplasia) that lead to frequent follow-ups. The prevalence of endometriosis in EOC is reported as range from 3.4% to 52.6% \[[@B21]\]. Also, in previous Korean multicenter study with CCC with endometriosis, 43.1% patients had CCC arising from endometriosis, which was higher than 18.3% in our study \[[@B22]\]. Different prevalence may be due to the different definitions used in studies for classifying the association with endometriosis. A number of criteria have been used to define EOC with endometriosis. The Van Gorp classification provides broad ranging criteria that emphasize identification of endometriosis alone or at any transition point within the surgical specimen coexisting with EOC \[[@B3]\]. The Sampson and Scott criteria apply strict histologic conditions for diagnosis of cancer arising from endometriosis based on demonstration of malignant transformation in the endometriosis glands leading to EOC \[[@B18][@B23]\]. This study applied the Sampson and Scott criteria for analysis.

Efforts to identify whether the EOC arising from endometriosis is clinically different entity are still ongoing. According to model suggested for EOC pathogenesis, type I tumors which consist of endometrioid, clear cell, mucinous and low-grade serous carcinoma, are presented with an indolent clinical behavior, are confined to the ovary, and, are relatively genetically stable \[[@B24]\]. Moreover, type I tumors exhibit a shared lineage with the corresponding pre-malignant lesion such as borderline tumors and endometriosis. Type I tumors are known to carry mutation of Kirsten rat sarcoma virus (*KRAS*), phosphatase and tensin homolog (*PTEN*), AT-rich interactive domain 1A (*ARID1A*) genes \[[@B3]\]. In contrast, type II tumors include high-grade serous and undifferentiated carcinoma, have a very aggressive clinical behavior, are usually advanced stage at presentation, often harbor *p53* gene mutations and are genetically unstable. EOC arising from endometriosis seems to show more similar characteristics to type I. According to previous studies, *ARID1A* mutations and loss of brahma-related gene (BRG)-associated factor 250a (BAF250a) expression were evident in ovarian CCC, especially in tumor and contiguous atypical endometriosis but not in distant endometriotic lesions, which may be considered as early occurrence for malignant change of endometriosis \[[@B25]\]. Also, atypical endometriosis and endometriosis-related cancers share similar molecular alterations, such as *PTEN* mutations, *ARID1A* mutations and up-regulation of hepatocyte nuclear factor-1-beta (HNF-1β), indicating mechanism of malignant change of endometriosis \[[@B26]\]. However, the clinical significance of loss of *ARID1A* in cancer arising from endometriosis has not been fully understood, and needs to be further elucidated.

This study has limitations due to its retrospective nature, limited number of patients from a single institution, and lack of detailed medical histories or treatment data after recurrence, which is related to survival outcomes. Also, we analyzed cancer associated with endometriosis group which include both CCC and EC, as we could not obtain a large number of data due to relatively low prevalence of EC and CCC. A larger number of cohort studies will help to obtain definite results in the future. Further analysis of the etiology for the early-stage and early age of patients with cancer arising from endometriosis is necessary.

Our data showed that patients with cancer arising from endometriosis were younger and had early-stage and low-grade disease compared to those without endometriosis. This may be related to the trend of better survival outcomes. However, in multivariate analysis for PFS and OS, cancer arising from endometriosis was not a significant prognostic factor, and survival differences between matched groups were not significant after propensity score matching.
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###### Supplementary Fig. 1

Distribution of propensity scores.

###### Supplementary Fig. 2

Histograms of propensity scores before and after matching.
